Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“Top Ten New and Exciting Data to Look Forward to at ASCO GU 2026 .
- KEYNOTE-B15
Neoadjuvant and Adjuvant Enfortumab Vedotin + Pembrolizumab
Cisplatin-Eligible Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Explores whether perioperative EV + IO improves outcomes beyond cisplatin-based chemotherapy in operable MIBC. - KEYNOTE-905
Perioperative Enfortumab Vedotin + Pembrolizumab
Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Steffen Rausch
Addresses treatment intensification in patients unable to receive cisplatin, a group with limited perioperative options. - RETAIN Trials (Integrated Analysis)
ctDNA-Guided Response-Adapted Bladder Preservation
Muscle-Invasive Bladder Cancer
Presenter: Pooja Ghatalia, MD
Evaluates whether ctDNA can guide bladder-sparing strategies and personalize perioperative decision-making. - IMvigor011 (Exploratory ctDNA Analysis)
ctDNA-Guided Adjuvant Atezolizumab
Muscle-Invasive Bladder Cancer
Examines molecular residual disease as a selection tool for adjuvant immunotherapy. - NIAGARA Biomarker Analysis
Urinary Tumor DNA (utDNA) and Circulating Tumor DNA (ctDNA)
In Patients Receiving Perioperative Durvalumab
Presenter: Michiel van der Heijden
Provides insight into biomarker-driven recurrence risk assessment in the perioperative setting. - RC48G001 (Phase 2)
Disitamab Vedotin in HER2-Expressing Previously Treated Advanced Urothelial Carcinoma
Presenter: Tom Powles
Clarifies the therapeutic relevance of HER2 targeting in advanced urothelial cancer. - LITESPARK-011 (Phase 3)
Belzutifan + Lenvatinib vs Cabozantinib
Advanced Renal Cell Carcinoma After Anti–PD-(L)1 Therapy
Compares HIF-2α inhibition plus VEGF blockade versus standard TKI therapy in the post-immunotherapy setting. - LITESPARK-022 (Phase 3)
Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab
Clear Cell Renal Cell Carcinoma
Presenter: Toni Choueiri
Assesses whether adding HIF-2α inhibition improves recurrence prevention beyond adjuvant IO alone. - K-COMPASS Model
Circulating KIM-1 and ctDNA as Prognostic Markers
Oligometastatic Clear Cell Renal Cell Carcinoma
Presenter: Chad Tang, MD
Explores circulating biomarkers to refine prognostication in oligometastatic disease. - EORTC 1333 / PEACE-3 (Final Overall Survival Results)
Enzalutamide With or Without Radium-223
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Enrique Gallardo
Final survival data will clarify the value of combining AR pathway inhibition with radiopharmaceutical therapy.
ASCO GU 2026 appears focused less on new drug introductions and more on optimizing patient selection, sequencing, and biomarker integration.
Looking forward to reviewing the full datasets”
Other articles featuring Amol Akhade on OncoDaily.